{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T14:41:21Z","timestamp":1649169681276},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T00:00:00Z","timestamp":1249948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s11912-009-0050-2","type":"journal-article","created":{"date-parts":[[2009,8,10]],"date-time":"2009-08-10T05:01:07Z","timestamp":1249880467000},"page":"371-377","source":"Crossref","is-referenced-by-count":0,"title":["Mantle cell lymphoma: Are current therapies changing the course of disease?"],"prefix":"10.1007","volume":"11","author":[{"given":"Christian","family":"Geisler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,11]]},"reference":[{"key":"50_CR1","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483","volume":"87","author":"D.D. Weisenburger","year":"1996","unstructured":"Weisenburger DD, Armitage JO: Mantle cell lymphoma: an entity comes of age. Blood 1996, 87:4483\u20134494.","journal-title":"Blood"},{"key":"50_CR2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","volume":"27","author":"P. Martin","year":"2009","unstructured":"Martin P, Chadburn A, Christos P, et al.: Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009, 27:1209\u20131213.","journal-title":"J Clin Oncol"},{"key":"50_CR3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A. Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, et al.: Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009, 27:511\u2013518.","journal-title":"J Clin Oncol"},{"key":"50_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","volume":"131","author":"M. Tiemann","year":"2005","unstructured":"Tiemann M, Schrader C, Klapper W, et al.: Histopathology, cell proliferation and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005, 131:29\u201338.","journal-title":"Br J Haematol"},{"key":"50_CR5","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","volume":"111","author":"O. Determann","year":"2008","unstructured":"Determann O, Hoster E, Ott G, et al.: Ki-67 predicts outcome in advanced mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy. Results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008, 111:2385\u20132387.","journal-title":"Blood"},{"key":"50_CR6","first-page":"750","volume":"7","author":"P. Jares","year":"2007","unstructured":"Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapies. Nat Med 2007, 7:750\u2013762.","journal-title":"Nat Med"},{"key":"50_CR7","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood 1997, 87:3909\u20133918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"50_CR8","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","volume":"16","author":"W. Hiddemann","year":"1998","unstructured":"Hiddemann W, Unterhalt M, Herrmann R, et al.: Mantlecell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998, 16:1922\u20131930.","journal-title":"J Clin Oncol"},{"key":"50_CR9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","volume":"113","author":"Y. Zhou","year":"2008","unstructured":"Zhou Y, Wang H, Wenjing F, et al.: Incidence trends of mantle cell lymphoma in the United States between 1992 and 1998. Cancer 2008, 113:791\u2013798.","journal-title":"Cancer"},{"key":"50_CR10","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/01.pas.0000208899.15859.cb","volume":"30","author":"A. Salar","year":"2006","unstructured":"Salar A, Juanpere N, Bellosillo B, et al.: Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 2006, 30:1274\u20131280.","journal-title":"Am J Surg Pathol"},{"key":"50_CR11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E. Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, et al.: A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood 2008, 111:558\u2013565.","journal-title":"Blood"},{"key":"50_CR12","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2007.12.0410","volume":"26","author":"E. Hartmann","year":"2008","unstructured":"Hartmann E, Fern\u00e1ndez V, Moreno V, et al.: Five-gene model to predict prognosis in mantle cell lymphoma. J Clin Oncol 2008, 26:4966\u20134972.","journal-title":"J Clin Oncol"},{"key":"50_CR13","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","volume":"16","author":"I.F. Khouri","year":"1998","unstructured":"Khouri IF, Romaguera J, Kantarjian H, et al.: Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem cell transplantation: an active regimen for mantle cell lymphoma. J Clin Oncol 1998, 16:3803\u20133809.","journal-title":"J Clin Oncol"},{"key":"50_CR14","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M. Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, et al.: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs event-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677\u20132684.","journal-title":"Blood"},{"key":"50_CR15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","volume":"71","author":"N.S. Andersen","year":"2003","unstructured":"Andersen NS, Pedersen L, Elonen E, et al.: Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003, 71:73\u201380.","journal-title":"Eur J Haematol"},{"key":"50_CR16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F. Lefrere","year":"2002","unstructured":"Lefrere F, Delmer A, Levy V, et al.: Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002, 16:587\u2013593.","journal-title":"Leukemia"},{"key":"50_CR17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/bmt.2008.349","volume":"43","author":"M. Magni","year":"2009","unstructured":"Magni M, di Nicola M, Carlo-Stella C, et al.: High-dose sequential chemotherapy and in vivo purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplant 2009, 43:509\u2013511.","journal-title":"Bone Marrow Transplant"},{"key":"50_CR18","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"C. Geisler","year":"2008","unstructured":"Geisler C, Kolstad A, Laurell A, et al.: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687\u20132693.","journal-title":"Blood"},{"key":"50_CR19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","volume":"144","author":"M.B. Veer van\u2019 t","year":"2009","unstructured":"van\u2019 t Veer MB, de Jong D, MacKenzie M, et al.: Highdose Ara-C and BEAM with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009, 144:524\u2013530.","journal-title":"Br J Haematol"},{"key":"50_CR20","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","volume":"113","author":"C.S. Tam","year":"2009","unstructured":"Tam CS, Bassett R, Ledesma C, et al.: Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144\u20134152.","journal-title":"Blood"},{"key":"50_CR21","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"J.E. Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, et al.: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013\u20137023.","journal-title":"J Clin Oncol"},{"key":"50_CR22","doi-asserted-by":"crossref","first-page":"121a","DOI":"10.1182\/blood.V110.11.121.121","volume":"110","author":"E.M. Epner","year":"2007","unstructured":"Epner EM, Unger J, Miller T, et al.: A multi center trial of hyperCVAD+rituxan in patients with newly diagnosed mantle cell lymphoma [abstract 387]. Blood 2007, 110:121a.","journal-title":"Blood"},{"key":"50_CR23","doi-asserted-by":"crossref","first-page":"121a","DOI":"10.1182\/blood.V110.11.121.121","volume":"110","author":"M. Dreyling","year":"2007","unstructured":"Dreyling M, Hoster E, Hermine O, et al.: European MCL Network: an update on current first line trials [abstract 388]. Blood 2007, 110:121a.","journal-title":"Blood"},{"key":"50_CR24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"J.M. Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZ, Cunningham D, et al.: European phase-II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317\u2013324.","journal-title":"J Clin Oncol"},{"key":"50_CR25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M. Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz SF, Cogliatti S, et al.: Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma. A study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23:705\u2013711.","journal-title":"J Clin Oncol"},{"key":"50_CR26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H. Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, et al.: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706\u2013714.","journal-title":"J Natl Cancer Inst"},{"key":"50_CR27","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"20","author":"O.M. Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of event-free survival. J Clin Oncol 2002, 20:1288\u20131294.","journal-title":"J Clin Oncol"},{"key":"50_CR28","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G. Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, et al.: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984\u20131992.","journal-title":"J Clin Oncol"},{"key":"50_CR29","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R. Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064\u20133071.","journal-title":"Blood"},{"key":"50_CR30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/10428190802641979","volume":"50","author":"H.E. Eve","year":"2009","unstructured":"Eve HE, Seymour JF, Rule SA: Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +\/- rituximab. Leuk Lymphoma 2009, 50:463\u2013465.","journal-title":"Leuk Lymphoma"},{"key":"50_CR31","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"M.J. Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, et al.: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 2005, 23:3383\u20133389.","journal-title":"J Clin Oncol"},{"key":"50_CR32","doi-asserted-by":"crossref","unstructured":"Rummel M, von Gruenhagen U, Niederle N, et al.: Bendamustine plus rituximab versus CHOP plus rituximab in first-line treatment of patients with follicular, indolent and mantle cell lymphomas. Results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL) [abstract 2596]. Presented at the 50th Annual Meeting of the American Society of Hematology. San Francisco, CA; December 6\u20139, 2008.","DOI":"10.1182\/blood.V112.11.2596.2596"},{"key":"50_CR33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","volume":"22","author":"N. Milpied","year":"1998","unstructured":"Milpied N, Gaillard F, Moreau P, et al.: High-dose therapy with stem-cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998, 22:645\u2013650.","journal-title":"Bone Marrow Transplant"},{"key":"50_CR34","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/sj.bmt.1705868","volume":"40","author":"C. Gisselbrecht","year":"2007","unstructured":"Gisselbrecht C, Bethge W, Duarte RF, et al.: Current status and future perspectives for yttrium-90(90Y)-ibritumomabtiuxetan in stem cell transplantation for non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 2007, 40:1007\u20131017.","journal-title":"Bone Marrow Transplant"},{"key":"50_CR35","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/MOH.0b013e3282efb17c","volume":"14","author":"S.I. Park","year":"2007","unstructured":"Park SI, Press OW: Radioimmunotherapy for treatment of lymphomas and other hematologic malignancies. Curr Opin Hematol 2007, 14:632\u2013638.","journal-title":"Curr Opin Hematol"},{"key":"50_CR36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","volume":"26","author":"A. Krishnan","year":"2008","unstructured":"Krishnan A, Nademanee A, Fung HC, et al.: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol 2008, 26:90\u201395.","journal-title":"J Clin Oncol"},{"key":"50_CR37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3324\/haematol.10608","volume":"92","author":"P. Dreger","year":"2007","unstructured":"Dreger P, Rieger M, Seyfarth B, et al.: Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 2007, 92:42\u201349.","journal-title":"Haematologica"},{"key":"50_CR38","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R. Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, et al.: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003\u20134008.","journal-title":"Blood"},{"key":"50_CR39","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","volume":"12","author":"M. Ladetto","year":"2006","unstructured":"Ladetto M, Magni M, Pagliano G, et al.: Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006, 12:1270\u20131276.","journal-title":"Biol Blood Marrow Transplant"},{"key":"50_CR40","doi-asserted-by":"crossref","first-page":"386a","DOI":"10.1182\/blood.V110.11.1281.1281","volume":"110","author":"N.S. Andersen","year":"2007","unstructured":"Andersen NS, Pedersen LB, Laurell A, et al.: Successful preemptive treatment of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma [abstract 1281]. Blood 2007, 110:386a.","journal-title":"Blood"},{"key":"50_CR41","doi-asserted-by":"crossref","unstructured":"Hitz F, Martinelli G, Zucca E, et al., on behalf of the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland: A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36\/03. Hematol Oncol 2009 Mar 8 (Epub ahead of print).","DOI":"10.1002\/hon.891"},{"key":"50_CR42","doi-asserted-by":"crossref","unstructured":"Garbo LE, Flynn P, MacRae MA, et al.: Results of a phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma. Invest New Drugs 2008, 9191\u20139197.","DOI":"10.1007\/s10637-008-9191-7"},{"key":"50_CR43","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","volume":"104","author":"M.B. Maris","year":"2004","unstructured":"Maris MB, Sandmaier B, Storer B, et al.: Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004, 104:3535\u20133542.","journal-title":"Blood"},{"key":"50_CR44","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A. Goy","year":"2009","unstructured":"Goy A, Bernstein SH, Kahl BS, et al.: Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20:520\u2013525.","journal-title":"Ann Oncol"},{"key":"50_CR45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","volume":"145","author":"O.A. O\u2019Connor","year":"2009","unstructured":"O\u2019Connor OA, Moskowitz C, Portlock C, et al.: Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol 2009, 145:34\u201339.","journal-title":"Br J Haematol"},{"key":"50_CR46","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","volume":"26","author":"A.A. Chanan-Kahn","year":"2008","unstructured":"Chanan-Kahn AA, Cheson BD: Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008, 26:1544\u20131552.","journal-title":"J Clin Oncol"},{"key":"50_CR47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","volume":"145","author":"T.M. Habermann","year":"2009","unstructured":"Habermann TM, Lossos IS, Justice G, et al.: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344\u2013349.","journal-title":"Br J Haematol"},{"key":"50_CR48","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"T.E. Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, et al.: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23:5347\u20135356.","journal-title":"J Clin Oncol"},{"key":"50_CR49","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","volume":"113","author":"S.M. Ansell","year":"2008","unstructured":"Ansell SM, Inwards DJ, Rowland KM, et al.: Lowdose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008, 113:508\u2013514.","journal-title":"Cancer"},{"key":"50_CR50","doi-asserted-by":"crossref","first-page":"44a","DOI":"10.1182\/blood.V110.11.44.44","volume":"110","author":"C.B. Reeder","year":"2007","unstructured":"Reeder CB, Gornet MK, Habermann TM, et al.: A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL) [abstract 121]. Blood 2007, 110:44a.","journal-title":"Blood"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-009-0050-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-009-0050-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-009-0050-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T09:04:00Z","timestamp":1590051840000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-009-0050-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,11]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s11912-009-0050-2","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,11]]}}}